This first installment of a six-part series—authored by Hinesh Patel, MCMI ChMC of CNM LLP, Chris Raphaely of Cozen O’Connor, Nathan Cali of NOBLE Capital Markets, and Matt Podowitz of Pathfinder Advisors—explores the timely and strategic reasons why European companies are pursuing acquisitions in the U.S. middle-market health care and life sciences (HCLS) sector.
The article also emphasizes the mutual benefits of cross-border M&A, noting how U.S. companies stand to gain from European capital, expertise, and regulatory know-how, while European investors can capitalize on the U.S.’s dominant position in global health care spending and innovation. With government policies supporting cost efficiency and accelerated approval pathways, as well as rising private equity interest, the U.S. middle-market HCLS space offers a timely opportunity to form high-impact partnerships and unlock value. This strategic moment invites stakeholders on both sides of the Atlantic to collaborate, driving growth, innovation, and long-term competitive advantage in a rapidly evolving health care ecosystem.
To read more, click here.